Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBI81F
|
|||
| Drug Name |
AMG 397
|
|||
| Synonyms |
UNII-BO0V7196L2; BO0V7196L2; Murizatoclax; Murizatoclax [USAN]; SCHEMBL21040009; WHO 11281; (13S,31R,32R,4R,5E,8S,9R)-6'-Chloro-4-methoxy-8,9-dimethyl-4-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-3',4'-dihydro-12H,14H,2'Hspiro(10lambda6-thia-11-aza-1(5,7)-(1,5)benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-13,1'-naphthalene)-10,10,12-trione; 2245848-05-7; Spiro(5,7-etheno-1H,11H-cyclobut(i)(1,4)oxazepino(3,4-f)(1,2,7)thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen)-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-16-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-, 10,10-dioxide, (1'S,11R,12S,14E,16R,16aR,18aR)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Refractory hematologic malignancy [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C42H57ClN4O5S
|
|||
| Canonical SMILES |
CC1CC=CC(C2CCC2CN3CC4(CCCC5=C4C=CC(=C5)Cl)COC6=C3C=C(C=C6)C(=O)NS(=O)(=O)C1C)(CN7CCN8CCCCC8C7)OC
|
|||
| InChI |
1S/C42H57ClN4O5S/c1-29-8-6-18-42(51-3,27-45-20-21-46-19-5-4-10-35(46)25-45)37-14-11-33(37)24-47-26-41(17-7-9-31-22-34(43)13-15-36(31)41)28-52-39-16-12-32(23-38(39)47)40(48)44-53(49,50)30(29)2/h6,12-13,15-16,18,22-23,29-30,33,35,37H,4-5,7-11,14,17,19-21,24-28H2,1-3H3,(H,44,48)/b18-6+/t29-,30+,33-,35+,37+,41-,42-/m0/s1
|
|||
| InChIKey |
BJTFTQIBRVBSBH-VCQPVEJUSA-N
|
|||
| CAS Number |
CAS 2245848-05-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | |||
| CCKR signaling map ST | ||||
| Pathway Interaction Database | E2F transcription factor network | |||
| Direct p53 effectors | ||||
| IL6-mediated signaling events | ||||
| HIF-1-alpha transcription factor network | ||||
| WikiPathways | Apoptosis | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| Apoptosis Modulation and Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03465540) Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.